RPL7A Antibody

What is RPL7A?

RPL7A is a conserved ribosomal protein encoded by the RPL7A gene (NCBI Gene ID: 6130) and is essential for ribosome assembly and translational fidelity . Beyond its canonical role, RPL7A interacts with nuclear hormone receptors (e.g., thyroid hormone receptor, retinoic acid receptor) to regulate gene expression and cellular differentiation .

Key Applications of RPL7A Antibodies

RPL7A antibodies are widely used in basic and clinical research. Their applications include:

• Western Blot (WB): Detects RPL7A at ~30 kDa in human, mouse, and rat samples .

• Immunohistochemistry (IHC): Localizes RPL7A in formalin-fixed tissues (e.g., lung carcinoma, breast cancer) .

• Immunofluorescence (IF): Visualizes RPL7A in cytoplasmic and nucleolar compartments .

• Immunoprecipitation (IP): Isolates RPL7A-protein complexes (e.g., ribosomal subunits) .

Recommended Dilutions:

Validation and Specificity

RPL7A antibodies exhibit high specificity across species and experimental conditions:

• Species Reactivity: Human, mouse, rat (validated in WB, IHC, IF) .

• Key Validation Studies:

  • Detects RPL7A in MCF7 cells, mouse liver, and rat kidney .

  • Confirms RPL7A upregulation in axon-regenerating retinal ganglion cells (RGCs) post-injury .

  • Distinguishes RPL7A isoforms in S. cerevisiae paralog studies .

Ribosome Biogenesis and Disease

• Depletion of RPL7A disrupts 60S subunit assembly, impairing rRNA processing and Ty1 retrotransposon mobility in yeast .

• In Alzheimer’s disease, RPL7A dysfunction correlates with ribosome stalling and toxic APP fragment accumulation .

Neuroregeneration

• Upregulating RPL7A in injured RGCs promotes axon regeneration and neuronal survival in murine models .

Autoimmunity

• Anti-RPL7A autoantibodies are implicated in systemic lupus erythematosus (SLE) diagnostics. Panels combining anti-RPL7A with anti-RPLP2 and anti-PARP1 improve SLE detection specificity .

Clinical and Diagnostic Relevance

• SLE Biomarker Panels: Anti-RPL7A IgG levels correlate with disease activity and clinical features like rash and thrombocytopenia .

• Cancer Research: RPL7A overexpression is linked to tumor progression (e.g., non-small cell lung cancer) .